Module Overview, Study Strategies, Impetigo, and Measles
Course Logistics and Participation
Questions and General Participation: Please use the chat box for questions. Video or audio participation is encouraged, especially for clinical case presentations and discussions.
Engagement: Actively participate by raising your hand or contributing via chat. This fosters deeper conversations and allows for bringing topics to real life through shared personal or professional experiences.
Adult Learning Environment: Students are encouraged to manage their learning needs, including taking breaks if necessary.
Guidance on Study Notes and Learning Approach
Addressing Study Notes Concern: A student asked whether to focus on the live lecture, prerecorded lecture, or readings, especially if readings contain additional information.
Recommended Approach: The instructor suggests a specific sequence for maximizing learning:
Re-watch Prerecorded Lecture First: This provides a broad overview of the major topics covered in each module. Students can print notes or make their own during this review.
Consult Readings Second: After the prerecorded lecture, delve into the readings. Focus on supplementing concepts that may not have been clearly explained or fully grasped from the prerecorded lecture. This helps avoid immediately going to external sources like YouTube, which can be time-consuming and may not be tailored to the course content.
Attend Live Class: Come to class prepared with questions, potentially for clinical consults or for direct messaging colleagues. This live session is for further discussion and clarification.
Clinical Case Presentations
Purpose: These presentations are designed for students to convey information to their colleagues and to develop concept mapping skills.
Concept Mapping Focus: The primary goal is to map out how pathophysiology impacts signs and symptoms, leads to specific treatments and therapeutics, and informs the ultimate patient management and integrated practicum (IP).
Testability: While clinical case presentations are fair game for testing, they are considered supplementary to the core course material. The foundational preparation for exams should focus on prerecorded lectures, readings, and professor's slides.
Specific Examples: For instance, Systemic Lupus Erythematosus (SLE) might be discussed, but the focus would be on identifying its hypersensitivity reaction type and how it affects multiple body systems, rather than extensive detail on all aspects of SLE.
Impetigo: Clinical Case Presentation Summary
Presenter: Jerry
Topic: Impetigo, with a scenario of children in a local daycare presenting with symptoms.
Presentation Objectives: Identify the causative microorganism, compare/contrast clinical manifestations of the three types (non-bullous, bullous, ecthyma), discuss treatment options, explain why it's common in children, and outline parental prevention strategies.
Definition: Impetigo is a highly contagious bacterial skin infection, primarily affecting children aged 2-5 years old.
Risk Factors:
Crowded living conditions and poor sanitation (e.g., improper handwashing, poor personal hygiene).
Prevalence in mid-to-late summer, especially in hot and humid climates.
Daycare facilities due to close contact among children.
Causative Microorganisms:
Staphylococcus aureus (S. aureus).
Beta-hemolytic Streptococcus Group A (GAS).
S. aureus can colonize the nares, but these bacteria typically do not cause infection unless there's a break in the skin integrity.
Pathophysiology:
Primary Infection: Occurs through minor breaks in the skin.
Secondary Infection: Can develop in areas with pre-existing dermatoses (e.g., eczema) or infestations, or surgical incisions.
Bacteria proliferate in the epidermis. Staphylococci produce bacteriocins, which cause blister formation.
Characteristic Lesion: Classic golden-yellow crusts. These open and erode lesions seep bacterial toxins.
Transmission: Direct contact (e.g., hand-to-mouth) or indirect contact (e.g., sharing contaminated objects like cups or toys).
Types of Impetigo:
Non-bullous (Mild):
Caused by S. aureus or GAS.
Typically colonizes around the mouth, nose, and on the hands.
Often asymptomatic with lesions 1-3 cm, which can be scattered, merge, or spread.
Usually resolves within 2-3 weeks.
Treatment: Topical antibiotics like mupirocin or fusidic acid.
Bullous (Moderate):
Exclusively caused by S. aureus.
Affects similar areas, often seen on the face or intertriginous areas (skin folds).
Presents as superficial blisters containing clear yellow or cloudy fluid, highly prone to bursting, leading to induration.
Treatment: Requires both topical and systemic antibiotics. First-line systemic antibiotics (based on Mums infection guidelines) include cloxacillin, clindamycin, and doxycycline. Swabbing is done to identify the specific microorganism. If Methicillin-resistant Staphylococcus aureus (MRSA) is suspected, beta-lactam antibiotics are avoided.
Ecthyma (Severe):
Develops if non-bullous or bullous impetigo goes untreated.
Characterized by ulcerated wounds with a thick, erythematous (red) halo, often tender.
Common in inaccessible sites, as seen in homeless individuals or soldiers in moist conditions.
Potential Complications: Glomerulonephritis, necrotizing fasciitis, and septic shock syndrome.
Prevention:
Educating parents on proper handwashing techniques.
Use of benzoyl peroxide washes for hands and potentially infected body areas.
Isolation of infected personal items such as washcloths, towels, drinking glasses, and bed linens.
Discussion Insights:
Recurrent Impetigo: Common in certain populations (e.g., Indigenous communities in northern Manitoba) due to crowded living conditions and challenges with hygiene. Such cases often lead to back-to-back systemic antibiotic treatments (e.g., Septra, Keflex, clindamycin, doxycycline).
Intranasal Mupirocin: Sometimes used preventatively to reduce colonization in the nares in recurrent cases, though its scientific efficacy is debated, especially given that colonization can occur in other areas (nasolabial folds, mouth corners, any skin opening).
Mupirocin Mechanism: It inhibits bacterial protein synthesis by interfering with RNA synthesis, not a beta-lactam antibiotic.
Topical vs. Systemic Treatment: Topical antibiotics are used for superficial epidermal infections, while systemic antibiotics are necessary when the infection extends into the dermis or deeper, preventing spread into the vasculature.
Antibiotic Resistance: A significant concern with recurrent infections. Bacteria can adapt by altering protein attachments, reducing antibiotic effectiveness. For suspected MRSA, systemic treatment generally avoids beta-lactams and relies on targeted antibiotics based on culture sensitivities.
Glomerulonephritis: A observed complication, particularly in recurrent impetigo.
Co-morbidities: Impetigo often coexists with other conditions like eczema or infestations (e.g., scabies), especially in vulnerable populations residing in close proximity (e.g., encampments).
Measles: Clinical Case Presentation Summary
Presenter: Sonia
Topic: Measles.
Causative Agent: Measles virus, an enveloped, single-stranded negative-sense RNA virus belonging to the Morbillivirus genus of the Paramyxoviridae family.
Viral Proteins: The genome encodes 8 proteins, including six structural (N, P, M, F, H, L) and two non-structural (V and C).
N (Nucleoprotein): Protects the viral RNA genome.
P (Phosphoprotein): Cofactor for RNA polymerase.
M (Matrix Protein): Involved in viral assembly and budding.
F (Fusion Protein): Mediates viral and host cell membrane fusion.
H (Hemagglutinin): Responsible for attachment to host cell receptors.
L (Large Protein): RNA-dependent RNA polymerase, essential for replication and transcription.
V and C (Non-structural Proteins): Suppress the host immune response and block interferon production.
Risk Factors: Any individual lacking immunity or who is non-immune.
Transmission: Airborne, primarily through inhalation of infected droplets.
Pathophysiology:
Initial infection of lymphocytes, dendritic cells, and alveolar macrophages upon inhalation.
Local spreading begins in lymphoid tissue.
Viremia occurs, spreading the virus to organs like the lungs, intestines, and brain.
Virus in dendritic cells and lymphocytes infects respiratory epithelial cells.
Shedding of epithelial cells triggers coughing and sneezing, facilitating further transmission and perpetuating the cycle.
Incubation Period: 10 to 14 days.
Clinical Features (Classic Symptoms):
Prodromal Phase: Coryza (running nose), conjunctivitis (pink eye), cough.
Koplik Spots: Pathognomonic white patches on the buccal mucosa.
Systemic Symptoms: Fever, often coinciding with viremia.
Maculopapular Rash: Appears after viral dissemination, starting on the face, spreading to the trunk, and then to the extremities, due to perivascular and lymphatic infiltration.
Viral Immune Evasion: Non-structural V and C proteins suppress interferon production, leading to early immune suppression and enabling rampant viral replication.
Host Immune Response:
Humoral Level (Extracellular):
IgM antibodies appear 3-4 days after rash onset and persist for 6-8 weeks, indicating an acute infection.
IgA antibodies are produced against the viral nucleoprotein (N).
Neutralizing IgG antibodies against hemagglutinin (H) confer lifelong immunity.
Cellular Level (Intracellular):
Th1 Response: Primarily mediated by T helper cells, increasing interferon-gamma levels in the acute phase for viral clearance.
Th2 Response: Increases interleukins 4, 10, and 13 in later phases, modulating inflammation and aiding recovery.
Histological Level: Lymph node biopsies may show giant multinucleated lymphocytes in paracortical hyperplasia.
Immunosuppression: Measles virus can cause immunosuppression lasting weeks to years, increasing susceptibility to secondary bacterial infections.
Hypothesis: The infection may induce proliferation of measles-specific lymphocytes that replace established memory cells, leading to